Cargando…
Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
SIMPLE SUMMARY: Gastric and gastro-oesophageal junction cancers (GC) are the fourth cause of cancer-related deaths, representing an international problem which needs a proper assessment. Beyond being an aggressive disease, which rapidly progress to different lines of treatment, patients suffering GC...
Autores principales: | Alsina, Maria, Tabernero, Josep, Diez, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945913/ https://www.ncbi.nlm.nih.gov/pubmed/35326560 http://dx.doi.org/10.3390/cancers14061408 |
Ejemplares similares
-
How I treat gastric adenocarcinoma
por: Alsina, Maria, et al.
Publicado: (2019) -
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011) -
Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations
por: Lee, Amy H., et al.
Publicado: (2022) -
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019) -
Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020)